350 руб
Журнал «Технологии живых систем» №5 за 2010 г.
Статья в номере:
ГЕНЕТИЧЕСКИЕ И ЭКОЛОГИЧЕСКИЕ ФАКТОРЫ РИСКА И УСТОЙЧИВОСТИ К РАКУ МОЛОЧНОЙ ЖЕЛЕЗЫ
Ключевые слова: рак молочной железы коэффициенты смертности корреляция Спирмена регрессионный анализ аллели генов экологические фактор
Авторы:
Лев Арамович Пирузян - академик, д.м.н., научный руководитель Центра теоретических проблем физико-химической фармакологии РАН (Москва) Каринэ Сергеевна Гюльазизова - соискатель д.б.н., Центр теоретических проблем физико-химической фармакологии РАН Ирина Сергеевна Николаева - д.м.н., зав. лабораторией этнической фармакологической метрологии, Центр теоретических проблем физико-химической фармакологии РАН Анатолий Сергеевич Кабанкин - д.б.н., гл. науч. сотрудник лаборатории этнической фармакологической метрологии, Центр теоретических проблем физико-химической фармакологии РАН Нэла Эмировна Пынько - науч. сотрудник лаборатории этнической фармакологической метрологии, Центр теоретических проблем физико-химической фармакологии РАН Галина Петровна Сухинина - к.м.н., ст. науч. сотрудник лаборатории этнической фармакологической метрологии, Центр теоретических проблем физико-химической фармакологии РАН Андрей Дмитриевич Радкевич - науч. сотрудник лаборатории этнической фармакологической метрологии, Центр теоретических проблем физико-химической фармакологии РАН Алия Рашидовна Кузнецова - мл. науч. сотрудник, Центр теоретических проблем физико-химической фармакологии РАН Людмила Александровна Радкевич - д.б.н., гл. науч. сотрудник, Ученый секретарь, Центр теоретических проблем физико-химической фармакологии РАН. E-mail: rla2001@mail.ru
Аннотация:
В результате исследований корреляционной связи коэффциентов смерт¬ности (КС) от рака молочной железы с генетическими и экологическими факторами установлено, что частоты встречаемости (ЧВ) в популяциях аллелей NAT2*5 и COMT+472, потребления протеина, жира и географическая широта связаны положительной корреляционной связью, а ЧВ аллелей СYP1A1*2C, NAT2*4 и GSTM1*0 связаны с КС отрицательной связью.
Страницы: 3-13
Список источников
  1. Goetz M.P., Knox S.K., Suman V.J., Rae J.M., Safgren S.L., Ames M.M., Visscher D.W., Reynolds C., Couch F.J., Lingle W.L., Weinshilboum R.M., Fritcher E.G., Nibbe A.M., Desta Z., Nguyen A., Flockhart D.A., Perez E.A., Ingle J.N. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen // Breast Cancer Res Treat. 2007. V. 101(1). P. 113-21.
  2. Goetz M.P., Rae J.M., Suman V.J., Safgren S.L., Ames M.M., Visscher D.W., Reynolds C., Couch F.J., Lingle W.L., Flockhart D.A., Desta Z., Perez E.A., Ingle J.N. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes // J. Clin. Oncol. 2005. V. 23(36). P. 9312-8.
  3. Kelsey J. L., Gammon M. D., John E. M. Reproductive factors and breast cancer // Epidemiol. Rev. 1993. V.15. P. 36 - 47.
  4. Long J.R., Cai Q., Shu X.O., Cai H., Gao Y.T., Zheng W.Genetic polymorphisms in estrogen-metabolizing genes and breast cancer survival // Pharmacogenet Genomics. 2007. V.17(5). P.331-8.
  5. Tozlu S., Girault I., Vacher S., Vendrell J., Andrieu C., Spyratos F., Cohen P., Lidereau R. Bieche. Identification of novel genes that co-cluster with estrogen receptor alpha in breast tumor biopsy specimens, using a large-scale real-time reverse transcription-PCR approach // Endocr. Relat. Cancer. 2006. V. 13(4). P. 1109 - 20.
  6. Nakajima M., Komagata S., Fujiki Y., Kanada Y., Ebi H., Itoh K., Mukai H., Yokoi T., Minami H. Genetic polymorphisms of CYP2B6 affect the pharmacokinetics / pharmacodynamics of cyclophosphamide in Japanese cancer patients // Pharmacogenet Genomics. 2007. V. 17(6). P. 431-45.
  7. Bosch T.M., Meijerman I., Beijnen J.H., Schellens J.H.Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer // Clin. Pharmacokinet. 2006. V. 45(3). P. 253 - 85.
  8. Parl F.F., Egan K.M., Li C., Crooke P.S. Estrogen exposure, metabolism, and enzyme variants in a model for breast cancer risk prediction // Cancer Inform. 2009. V. 7. P. 109 - 21.
  9. Surekha D., Sailaja K., Rao D.N., Padma T., Raghunadharao D., Vishnupriya S. Association of CYP1A1*2 polymorphisms with breast cancer risk: a case control study // Indian J. Med. Sci. 2009. V. 63(1). P. 13 - 20.
  10. Torresan C., Oliveira M.M., Torrezan G.T., de Oliveira S.F., Abuázar C.S., Losi-Guemba­rovski R., Lima R.S., Urban C.A., Cavalli I.J., Ribeiro E.M.// Clin. Exp. Med. 2008. V. 8(2). P. 65 - 71.
  11. Bershteĭn L.M., Ulybina Iu.M., Pozharisskiĭ K.M., Imianitov E.N. Analysis of polymorphisms in genes of insulin receptor substrate-1 and enzymes involved in estrogen biosynthesis and metabolism among breast cancer patients with BRCA1 mutations // Vopr. Onkol. 2009. V.55(2). P. 158-64.
  12. Welfare M.R., Cooper J., Bassendine M.F., Daly A.K. Relationship between acetylator status, smoking, diet and colorectal cancer risk in north-east England // Carcinogenesis. 1997. V. 18. P. 1351 - 1354.
  13. Roberts-Thomson I.C., Ryan P., Khoo K.K., Hart W.J., McMichael A.J., Butler R.N. Diet, acetylator phenotype and risk of colorectal neoplasia // Lancet. 1996. V. 347. P. 1372-1374.
  14. Chen J., Stampfer M.J., Hough H.L. et al. A Prospective study of N-acetyltransferase genotype, red meat intake, and risk of colorectal cancer // Cancer. Res. 1998. V. 58. P. 3307-3311.
  15. Ralph J. Delfino, Rashmi Sinha, Cynthia Smith, John West, Edward White, Henry J. Lin, Shu-Yuan Liao, Jason S.Y. Gim, Hoang L. Ma, John Butler and Hoda Anton-Culver. Breast cancer, heterocyclic aromatic amines from meat and N-acetyltransferase 2 genotype // Carcinogenesis. 2000. V.21. N. 4. P. 607 - 615.
  16. McLeod HL, PGENI Project. URL: http://pgeni.im.wustl.edu/gene.asp.gid=573
  17. Brockton N., Little J., Sharp L., Cotton S.C.
    N-Acetyltransferase Polymorphisms and Colorectal Cancer: A HuGE Review// Am. J. Epidemiol. 2000. V. 151(9). P. 846 - 61.
  18. Ognjanovic S., Yamamoto J., Maskarinec G., Le Marchand L.NAT2, meat consumption and colorectal cancer incidence: an ecological study among 27 countries // Cancer Causes Contro.l. 2006. V. 17. P. 1175-1182.
  19. Sotiria B., Giannoulis F. Arylamine N-Acetyl­transferases: What We Learn from Genes and Genomes // Drug Metabolism Reviews. 2000. V. 537. N. 3. P. 511 - 564.
  20. Eichelbaum M., Ingelman-Sundberg M., Evans W.E. Pharmacogenomics and Individualized Drag Therapy // Annu. Rev. Med. 2006. V. 57. P. 119 - 37.
  21. Alison M. Dunning, Catherine S. Healey, Paul D. P. Pharoah, M. Dawn Teare, Bruce A. J. Ponder Douglas F. Easton. A Systematic Review Of Genetic Polymorphisms and Breast Cancer Risk // Cancer Epidemiology Biomarkers & Prevention. 1999. V. 8. P. 843 - 854.
  22. Sergentanis T.N., Economopoulos K.P. Four polymorphisms in cytochrome P450 1A1 (CYP1A1) gene and breast cancer risk: a meta-analysis // Breast Cancer Res. Treat. 2009. Dec. V. 25.
  23. Helliwell P.S., Ibrahim G.Ethnic differences in responses to disease modifying drugs // Rheumatology (Oxford). 2003. V. 42. P. 1197 - 1201.
  24. Garte S., Gaspari L., Alexandrie A.K., Ambrosone C., Autrup H., Autrup J.L., Baranova H., Bathum L., Benhamou S., Boffetta P. et al. Metabolic Gene Polymorphism Frequencies in Control Populations. //Cancer Epidemiology Biomarkers & Prevention. 2001. V.10. P. 1239-1248.
  25. Alvan G., Bechtel P., Iselius L., Gundert"Remy U.Hydroxilation polymorphisms of debrisoquine and mephenutoin in European populations // Eur. J. Clin. Pharmacol. 1990. V. 39. P. 533-537.
  26. Takata Y., Maskarinec G., Le Marchand L. Breast density and polymorphisms in genes coding for CYP1A2 and COMT: the Multiethnic Cohort. // BMC Cancer. 2007. V. 7. P. 30.
  27. Chida M., Yokoi T., Fukui T., Kinoshita M., Yokota J., Kamataki T. Detection of three genetic polymorphisms in the 5'-flanking region and intron 1 of human CYP1A2 in the Japanese population // Jpn. J. Cancer. Res. 1999. V. 90(9). P. 899-902.
  28. Hiratsuka M., Takekuma Y., Endo N., Narahara K., Hamdy S.I., Kishikawa Y., Matsuura M., AgatsumaY., InoueT., Mizugaki M. Allele and genotype frequencies of CYP2B6 and CYP3A5 in the Japanese population // Eur. J. Clin. Pharmacol. 2002. V. 58(6). P. 417-21.
  29. Terry P.D., Goodman M. Is the association between cigarette smoking and breast cancer modified by genotype - A review of epidemiologic studies and meta-analysis // Cancer Epidemiol Biomarkers Prev. 2006. V. 15(4). P. 602 - 11.
  30. Food Balance Sheets, FAOSTAT (2004) Software. URL: http://faostat.fao.org.
  31. ЕжегодникВОЗза 1980 - 1983 годы; WHO Statistics, Mortality Database, Select country/year, Table 1. URL: http://www.who.int/whosis/.
  32. Olesen O.F., Bennike B., Dam H., Mellerup E. Association of the 5-HT2A receptor gene polymorphism 102T/C with ischemic stroke // J. Mol. Neurosci. 2006. V. 30(3). P. 323-8.
  33. ALFRED. URL: http://pgeni.unc.edu/; http://pgeni.im.wustl.edu/.
  34. Gsur A., Haidinger G., Hollaus P., Herbacek I., Madersbacher S., Trieb K., Pridun N., Mohn-Staudner A., Vetter N., Vutuc C., Micksche M. Genetic polymorphisms of CYP1A1 and GSTM1 and lung cancer risk //  Anticancer Res. 2001. V. 21(3C). P. 2237 - 42.
  35. Pagliuso R.G., Abbud-Filho M., Alvarenga M.P., Ferreira-Baptista M.A., Biselli J.M., Biselli P.M., Goloni-Bertollo E.M., Pavarino-Bertelli E.C. // Transplant Proc. 2008. V. 40(3). P. 743-5.
  36. Xu Y.F., Pan Q.H., Cui C., Chen L.Z., Feng Q.S., Zeng Y.X., Jia W.H. Association of nasopharyngeal carcinoma risk with cytochrome P450 CYP1A1 gene polymorphisms // Zhonghua Yu Fang Yi Xue Za Zhi. 2009. V. 43(7). P. 586-90. URL: http://www.spss.ru
  37. Li M., Guan T.Y., Li Y., Na Y.Q. Polymorphisms of GSTM1 and CYP1A1 genes and their genetic susceptibility to prostate cancer in Chinese men // Chin. Med. J. (Engl). 2008. V. 121(4). P. 305-8.
  38. Anttila S., Tuominen P., Hirvonen A., Nurminen M., Karjalainen A., Hankinson O., Elovaara E. CYP1A1 levels in lung tissue of tobacco smokers and polymorphisms of CYP1A1 and aromatic hydrocarbon receptor // Pharmacogenetics. 2001. V. 11(6). P. 501 - 9.
  39. Oyama T., Mitsudomi T., Kawamoto T., Ogami A., Osaki T., Kodama Y., Yasumoto K. Detection of CYP1A1 gene polymorphism using designed RFLP and distributions of CYP1A1 genotypes in Japanese // Int. Arch. Occup. Environ. Health. 1995. V. 67(4). P. 253-6.
  40. Chevrier C., Bahuau M., Perret C., Iovannisci D.M., Nelva A., Herman C., Vazquez M.P., Francannet C., Robert-Gnansia E., Lammer E.J., Cordier S. Genetic susceptibilities in the association between maternal exposure to tobacco smoke and the risk of nonsyndromic oral cleft // Am. J. Med. Genet. A. 2008. V. 146A(18). P.2396-406.
  41. Breuer M.A., Schmidt B., Schuphan I.Utility of Nicotiana tabacum cell suspension cultures expressing human CYP1A1, CYP1A2 and CYP3A4 to study the oxidative metabolism of the herbicide 14C-fluometuron // Drug. Metab. Lett. 2009. V.3(1). P. 18 - 27.
  42. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population // Eur. J. Clin. Pharmacol. 2003. V. 59(4). P. 303-12.
  43. FAO. URL: http://faostat.fao.org.
  44. URL: http://earth-info.nga.mil/gns/html/index.html
  45. Gaikovitch E.A., Cascorbi I., Mrozikiewicz P.M., Brockmöller J., Frötschl R., Köpke K., Gerloff T., Chernov J.N., Roots I. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population // Eur. J. Clin. Pharmacol. 2003. V. 59(4). P. 303-12.
  46. Murata M., Watanabe M., Yamanaka M., Kubota Y., Ito H., Nagao M., Katoh T., Kamataki T., Kawamura J., Yatani R., Shiraishi T. Genetic polymorphisms in cytochrome P450 (CYP) 1A1, CYP1A2, CYP2E1, glutathione S-transferase (GST) M1 and GSTT1 and susceptibility to prostate cancer in the Japanese population // Cancer Lett. 2001. V. 165(2). P. 171-7.
  47. Masimirembwa C.M., Dandara C., Sommers D.K., Snyman J.R., Hasler J.A.Genetic polymorphism of cytochrome P4501A1, microsomal epoxide hydrolase, and glutathione S-transferases M1 and T1 in Zimbabweans and Venda of southern Africa // Pharmacogenetics. 1998. V. 8(1). P. 83-5.
  48. Labuda D., Krajinovic M., Richer C., Skoll A., Sinnett H., Yotova V., Sinnett D.Rapid detection of CYP1A1, CYP2D6, and NAT variants by multiplex polymerase chain reaction and allele-specific oligonucleotide assay //Anal. Biochem. 1999. V. 275(1). P. 84 - 92.
  49. Meyer U.A., Zanger U.M. Molecular mechanisms of genetic polymorphisms of drug metabolism // Annu Rev. Pharmacol. Toxicol. 1997. V. 37. P. 269-96.
  50. Belogubova E.V., Kuligina E.Sh., Togo A.V., Karpova M.B., Ulibina J.M., Shutkin V.A., Hanson K.P., Popowski K., Mosyagin I., Cascorbi I., Hirvonen A., Imyanitov E.N. 'Comparison of extremes' approach provides evidence against the modifying role of NAT2 polymorphism in lung cancer susceptibility // Cancer Lett. 2005. V. 221(2). P. 177-83.
  51. Muiras M.L., Verasdonck P., Cottet F., Schächter F.Lack of association between human longevity and genetic polymorphisms in drug-metabolizing enzymes at the NAT2, GSTM1 and CYP2D6 loci // Hum Genet. 1998. V. 102(5). P. 526 - 32.
  52. Adams C.H., Werely C.J., Victor T.C., Hoal E.G., Rossouw G., van Helden P.D. Allele frequencies for glutathione S-transferase and N-acetyl­transferase 2 differ in African population groups and may be associated with oesophageal cancer or tuberculosis incidence //Clin Chem. Lab. Med. 2003. V. 41(4). P. 600-5.
  53. Wild C.P., Yin F., Turner P.C., Chemin I., Chapot B., Mendy M., Whittle H., Kirk G.D., Hall A.J. Environmental and genetic determinants of aflatoxin-albumin adducts in the Gambia // Int. J. Cancer. 2000. V. 86(1). P. 1 - 7.
  54. González M.V., Alvarez V., Pello M.F., Menéndez M.J., Suárez C., Coto E. Genetic polymorphism of N-acetyltransferase-2, glutathione S-transferase-M1, and cytochromes P450IIE1 and P450IID6 in the susceptibility to head and neck cancer // J. Clin. Pathol. 1998. V. 51(4). P. 294-8.
  55. Li T., Vallada H., Curtis D., Arranz M., Xu K., Cai G., Deng H., Liu J., Murray R., Liu X., Collier D.A. Catechol-O-methyltransferase Val158Met polymorphism: frequency analysis in Han Chinese subjects and allelic association of the low activity allele with bipolar affective disorder //Pharmacogenetics. 1997. V. 7(5). P.  49-53.
  56. de Chaldée M., Laurent C., Thibaut F., Martinez M., Samolyk D., Petit M., Campion D., Mallet J. Linkage disequilibrium on the COMT gene in French schizophrenics and controls //Am. J. Med. Genet. 1999. V. 88(5). P. 452 - 7.
  57. Gutiérrez B., Bertranpetit J., Guillamat R., Vallès V., Arranz M.J., Kerwin R., Fañanás L. Association analysis of the catechol O-methyltransferase gene and bipolar affective disorder // Am. J. Psychiatry. 1997. V. 154(1). P. 113-5.
  58. McLeod H.L., Syvänen A.C., Githang'a J., Indalo A., Ismail D., Dewar K., Ulmanen I., Sludden J. Ethnic differences in catechol O-methy­ltransferase pharmacogenetics: frequency of the codon 108/158 low activity allele is lower in Kenyan than Caucasian or South-west Asian individuals // Pharmacogenetics. 1998. V. 8(3). P. 195-9.
  59. Ellard G.A.Variations between individuals and populations in the acetylation of isoniazid and its significance for the treatment of pulmonary tuberculosis // Clin. Pharmacol. Ther. 1976. V. 19. P. 610-625.
  60. Miller B.A., Kolonel L.N., Bernstein L. et al. Racial/ ethnic patterns of cancer in the United States 1988-1992. National Cancer Institute, NIH Pub. 1996. N. 96-4104. Bethesda.
  61. Charrier J., Maugard C.M., Le Mevel B., Bignon Y.J. Allelotype influence at glutathione
    S-transferase M1 locus on breast cancer susceptibility // Br. J. Cancer. 1999. V.79(2). P. 346-53.
  62. Maugard C.M., Charrier J., Bignon Y.J. Allelic deletion at glutathione S-transferase M1 locus and its association with breast cancer susceptibility // Chem. Biol. Interact. 1998.
    V. 111 - 112. P. 365 - 75.
  63. Li Y., Millikan R.C., Bell D.A., Cui L., Tse C.K., Newman B., Conway K. Cigarette smoking, cytochrome P4501A1 polymorphisms, and breast cancer among African-American and white women // Breast Cancer Res. 2004. V. 6(4). P. R460-73.
  64. Lee K.M., Park S.K., Kim S.U., Doll M.A., Yoo K.Y., Ahn S.H., Noh D.Y., Hirvonen A., Hein D.W., Kang D. N-acetyltransferase (NAT1, NAT2) and glutathione S-transferase (GSTM1, GSTT1) polymorphisms in breast cancer //Cancer Lett. 2003. V. 196(2). P. 179-86.
  65. Анисимов В.Н. Световой режим, риск возникновения рака. Противоопухолевое действие мелатонина // РМЖ. 2007. Т. 15. № 25.
    С. 1915-1919.
  66. Новиков Н.Н. Воздействие ультрафиолетового излучения на человека // Ежемесячный обще
    медицинский журнал.mht ММА им. И.М. Сеченова. 2004. №6. C. 82-87.
  67. Enns M.W., Cox B.J., Levitt A.J., Levitan R.D., Morehouse R., Michalak E.E., Lam R.W. Personality and seasonal affective disorder: results from the CAN-SAD study // J. Affect. Disord. 2006. V. 93(1-3). P. 35-42.
  68. Moon H.K., Kim C.Y., Lee S.W. Exploratory correlations of dietary nutrients with prostate cancer mortality using over two decades of observations in Korea // Mol. Nutr. Food Res. 2009. V. 53(2). P. 185-90.